These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 6682193)

  • 1. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
    Schneider E; Hubener K; Fischer PA
    Neurology; 1983 Apr; 33(4):468-72. PubMed ID: 6682193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.
    Jellinger K
    J Neurol; 1982; 227(2):75-88. PubMed ID: 6180142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.
    Goetz CG; Tanner CM; Glantz RH; Klawans HL
    Neurology; 1985 May; 35(5):749-51. PubMed ID: 3990974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
    Marsden CD
    Drugs; 1998; 55 Suppl 1():17-22. PubMed ID: 9483166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic results with a new ergoline derivate (8-alpha-amino-ergoline, CU 32-085) in parkinsonian patients.
    Schneider E; Hubener K; Fischer PA
    Adv Neurol; 1984; 40():527-9. PubMed ID: 6695631
    [No Abstract]   [Full Text] [Related]  

  • 7. CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
    Rascol O; Fabre N; Teräväinen H; Poewe W; Lücking C; Rinne U; Dupont E; Hirt D; Hoyer M; Lataste X
    Clin Neuropharmacol; 1990 Aug; 13(4):303-11. PubMed ID: 2208182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine agonists as primary treatment in Parkinson's disease.
    Rinne UK
    Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394
    [No Abstract]   [Full Text] [Related]  

  • 9. Placebo-controlled study of mesulergine in Parkinson's disease.
    Jankovic J; Orman J; Jansson B
    Neurology; 1985 Feb; 35(2):161-5. PubMed ID: 3881692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine agonists in the treatment of Parkinson's disease.
    Rinne UK
    Adv Neurol; 1983; 37():141-50. PubMed ID: 6305175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine agonists and Parkinson's disease.
    Burton K; Calne DB
    Clin Neurol Neurosurg; 1984; 86(3):172-7. PubMed ID: 6091965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of parkinson's disease with bromocriptine.
    Lieberman A; Kupersmith M; Estey E; Goldstein M
    N Engl J Med; 1976 Dec; 295(25):1400-4. PubMed ID: 989885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesulergine (CU 32-085) in the treatment of Parkinson's disease.
    Rascol A; Montastruc JL; Rascol O; Senard JM
    Clin Neuropharmacol; 1986; 9(2):146-52. PubMed ID: 3708600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism.
    Schneider E; Baas H; Fischer PA; Japp G
    J Neurol; 1985; 232(1):24-8. PubMed ID: 3998771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Parkinson's disease with dopamine agonists: a review.
    Lieberman A; Neophytides A; Kupersmith M; Casson I; Durso R; Foo SH; Khayali M; Tartaro T; Goldstein M
    Am J Med Sci; 1979; 278(1):65-76. PubMed ID: 39452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of pergolide, a potent dopamine agonist, in Parkinson's disease.
    Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Walker R; Pact V
    Clin Pharmacol Ther; 1982 Jul; 32(1):70-5. PubMed ID: 7083733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CQA 206-291 in Parkinson's disease: an acute single escalating dosage study.
    Lang AE; Riley DE; Vachon L; Lataste X
    Can J Neurol Sci; 1990 Nov; 17(4):416-9. PubMed ID: 2276100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.